Pharmacogenetics is the search for heritable genetic polymorphisms that influence responses to drug therapy. The most important application of pharmacogenetics is to guide choosing agents with the greatest potential of efficacy and smallest risk of adverse drug reactions. Many studies focusing on druggene interactions have been published in recent years, some of which led to adaptation of FDA recommendations, indicating that we are on the verge of the clinical application of genetic information in drug therapy. This systematic review provides a comprehensive overview of the current knowledge on pharmacogenetics of all major drug classes currently used in the treatment of cardiovascular diseases.

cardiovascular disease, drug response, drug therapy, pharmacogenetics, single-nucleotide polymorphism, systematic review,
European Heart Journal
This work was funded by the European Commission 7th Framework Programme; grant id fp7/223004 - A PHArmacogenomic study of Statins in the Elderly at risk for cardiovascular disease (PHASE)
Erasmus MC: University Medical Center Rotterdam

Verschuren, J.J.W, Trompet, S, Wessels, J.A.M, Guchelaar, H.J, de Maat, M.P.M, Simoons, M.L, & Jukema, J.W. (2012). A systematic review on pharmacogenetics in cardiovascular disease: Is it ready for clinical application?. European Heart Journal (Vol. 33, pp. 165–175). doi:10.1093/eurheartj/ehr239